The insider sales are too small to be informative. The real risk is the $400M shelf registration and going-concern warning, monitor for any ATM drawdown or equity offering in the coming weeks, which would be highly dilutive. The Q1 beat and reaffirmed guidance provide near-term support, but the cash crunch is the dominant factor.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $7.14entry
- T+1 · 6mo ago +4.62%α +5.27% · $7.47
- T+5 · 6mo ago +25.63%α +24.01% · $8.97
- T+20 · 5mo ago +27.45%α +25.87% · $9.10
- T+60 · 3mo ago −71.57%α −76.42% · $2.03
Price Chart
How similar events traded
Executive Summary
Five Karyopharm insiders, including the CEO and C-suite, sold a total of $31K in open-market sales on May 14, 2026, the same day the company reported Q1 earnings. The sales are trivial relative to the $201M market cap (0.015%) and follow a pattern of stock grants on May 13, suggesting the sales are likely liquidity-driven to cover tax obligations or diversify, not a bearish signal. The cluster is amplified by the cross-filing context of a $400M shelf registration and going-concern warning, but the dollar amount is too small to be material.
Key Financial Metrics
Key Facts
- Five insiders sold a total of 3,254 shares for $31K on May 14, 2026, representing 0.015% of market cap.
- CEO Richard Paulson sold the largest portion: 2,203 shares for $21K.
- All five insiders received stock grants on May 13, 2026 (non-cash, $0 value), preceding the sales.
- The sales occurred on the same day as Q1 2026 earnings release (revenue $35.1M, up 17% YoY; EPS beat consensus by 29%).
- A $400M shelf registration (including $100M ATM) was filed 11 days prior, representing ~202% dilution risk.
- The company has a going-concern warning with cash runway only into late Q3 2026.
Financial Impact
Total insider sales of $31K, or 0.015% of $201M market cap, immaterial.
Risk Factors
- Massive potential dilution from $400M shelf registration (202% of market cap).
- Going-concern warning with cash runway only into late Q3 2026.
- Phase 3 SENTRY myelofibrosis trial missed second co-primary endpoint.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KPTI-1778875977454 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers